State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong, People's Republic of China.
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1090-7. doi: 10.1016/j.ijrobp.2010.11.063. Epub 2011 Aug 22.
To investigate the prognostic significance of prevertebral space involvement (PSI) in patients with nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT).
A retrospective review of data from 506 biopsy-proven, nonmetastatic NPCs was performed. Patients underwent magnetic resonance imaging examinations and received IMRT as their primary treatment.
In this series, 161 NPC patients (31.8%) had PSI. Parapharyngeal space (p < 0.001), skull base (p < 0.001), and paranasal sinuses (p = 0.009) were associated with PSI after multivariate analysis. The 4-year overall survival (OS), local relapse-free survival (LRFS), distant metastasis-free survival (DMFS) for NPC patients with and without PSI was 69.1% and 89.2% (p < 0.0001), 83.9% and 96.4% (p < 0.0001), and 71.6% and 89.6% (p < 0.0001), respectively. Multivariate analysis identified PSI as an independent negative prognostic factor for both OS (HR = 1.478-4.380; p = 0.001) and DMFS (HR = 1.389-4.174; p = 0.002). Patients with PSI had similar survival rates in OS and DMFS (p = 0.241 and p = 0.493, respectively) to that of T4 disease, while the differences between PSI and T3 disease in both OS and DMFS were distinctly significant (p = 0.029 and p = 0.029, respectively).
For NPC patients treated with IMRT, PSI was found to be an independent prognostic factor for both OS and DMFS. It seems reasonable that PSI should be classified as a T4 disease on the basis of the current American Joint Committee on Cancer staging classification criteria.
研究调强放疗(IMRT)治疗鼻咽癌(NPC)患者椎前间隙侵犯(PSI)的预后意义。
对 506 例经活检证实的非转移性 NPC 患者的数据进行回顾性分析。患者接受了磁共振成像检查,并接受了 IMRT 作为主要治疗方法。
在本系列中,161 例 NPC 患者(31.8%)有 PSI。多变量分析后,翼腭窝(p < 0.001)、颅底(p < 0.001)和鼻窦(p = 0.009)与 PSI 相关。有和无 PSI 的 NPC 患者的 4 年总生存率(OS)、局部无复发生存率(LRFS)、无远处转移生存率(DMFS)分别为 69.1%和 89.2%(p < 0.0001)、83.9%和 96.4%(p < 0.0001)、71.6%和 89.6%(p < 0.0001)。多变量分析确定 PSI 是 OS(HR = 1.478-4.380;p = 0.001)和 DMFS(HR = 1.389-4.174;p = 0.002)的独立预后不良因素。在 OS 和 DMFS 中,有 PSI 的患者与 T4 疾病的生存率相似(p = 0.241 和 p = 0.493),而 PSI 与 T3 疾病在 OS 和 DMFS 中的差异均有统计学意义(p = 0.029 和 p = 0.029)。
对于接受 IMRT 治疗的 NPC 患者,PSI 是 OS 和 DMFS 的独立预后因素。根据目前的美国癌症联合委员会分期分类标准,将 PSI 归类为 T4 疾病似乎是合理的。